Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

Xu,Ting; Du,Xiao‑Wen; Hu,Jun‑Biao; Zhu,Yong‑Feng; Wu,Hui‑Ling; Dai,Guo‑Ping; Shu,Yao‑Min; Ouyang,Jun

doi:10.3892/ol.2018.7745

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

Authors:
- Ting Xu
- Xiao‑Wen Du
- Jun‑Biao Hu
- Yong‑Feng Zhu
- Hui‑Ling Wu
- Guo‑Ping Dai
- Yao‑Min Shu
- Jun Ouyang
View Affiliations

Affiliations: Department of Urology, Jinhua People's Hospital, Jinhua, Zhejiang 321000, P.R. China, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: January 8, 2018 https://doi.org/10.3892/ol.2018.7745
Pages: 3814-3819

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of microRNA-96 (miR-96) in the proliferation, invasion and apoptosis of bladder cancer cell lines, and the associated mechanisms. The expression of miR‑96 and human ether‑à‑go‑go‑related (HERG1) potassium channel in the normal uroepithelium SV‑HUC‑1 cell line, and bladder cancer T24 and 5637 cell lines were examined using reverse transcription‑ polymerase chain reaction or/and western blotting. Transfection with miR‑96 inhibitor or scrambled control (SC) was used to study the biological activities of miR‑96 in bladder cancer cell lines. MTT, flow cytometric and Transwell assays were applied to detect cell viability, apoptosis and invasion, respectively. A dual‑luciferase reporter assay was applied to determine the association between miR‑96 and HERG1 expression. As demonstrated, miR‑96 was highly expressed in the two bladder cancer cell lines, particularly in T24 cells. Following transfection with miR‑96 inhibitor, miR‑96 expression was significantly reduced in the T24 cell line, compared with SC. The miR‑96 inhibitor suppressed cell proliferation and invasion, promoted apoptosis and arrested the cell cycle at the G1 phase. Consistently, HERG1 was also highly expressed in the two bladder cancer cell lines at the mRNA and protein level, but not in the normal uroepithelium cell line. The miR‑96 inhibitor also significantly decreased HERG1 expression compared with SC. The results of the dual‑luciferase reporter assay indicated that miR‑96 directly targeted wild‑type HERG1. In conclusion, miR‑96 inhibitor exhibited anticancer effects on bladder cancer cells by inhibiting proliferation and invasion of cells, and promoting their apoptosis. HERG1 was an important target of miR‑96. These results provided experimental evidence supporting miR‑96 as a therapeutic target for patients with bladder cancer.

View Figures

View References

1	Gan X, Lin X, He R, Lin X, Wang H, Yan L, Zhou H, Qin H and Chen G: Prognostic and clinicopathological significance of downregulated p16 expression in patients with bladder cancer: A systematic review and meta-analysis. Dis Markers. 2016:52596022016. View Article : Google Scholar : PubMed/NCBI
2	Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S and Drabick JJ: Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. Oncologist. 21:708–715. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cauberg Evelyne CC, de la Rosette JJ and de Reijke TM: Emerging optical techniques in advanced cystoscopy for bladder cancer diagnosis: A review of the current literature. Indian J Urol. 27:245–251. 2011. View Article : Google Scholar : PubMed/NCBI
4	Fahmy N, Lazo-Langner A, Iansavichene AE and Pautler SE: Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review. Can Urol Assoc J. 7:E740–E749. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mizuguchi Y, Takizawa T, Yoshida H and Uchida E: Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wang QX, Zhu YQ, Zhang H and Xiao J: Altered MiRNA expression in gastric cancer: A systematic review and meta-analysis. Cell Physiol Biochem. 35:933–944. 2015. View Article : Google Scholar : PubMed/NCBI
7	Gambari R, Brognara E, Spandidos DA and Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Nuew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 49:5–32. 2016. View Article : Google Scholar : PubMed/NCBI
8	Srivastava K and Srivastava A: Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 7:e509662012. View Article : Google Scholar : PubMed/NCBI
9	Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al: MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 6:e182862011. View Article : Google Scholar : PubMed/NCBI
10	Wu Z, Liu K, Wang Y, Xu Z, Meng J and Gu S: Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int. 15:1072015. View Article : Google Scholar : PubMed/NCBI
11	Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Müller SC and Ellinger J: Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. PLoS One. 10:e01172842015. View Article : Google Scholar : PubMed/NCBI
12	Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC and Ellinger J: Circulating microRNAs in serum: Novel biomarkers for patients with bladder cancer? World J Urol. 32:353–358. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M and Enokida H: Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Kawahara K, Nishiyama K, Seki N and Nakagawa M: MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: Correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 102:522–529. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhu G, Wang X, Wu S and Li Q: Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP⁺-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int. 60:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lv Q, Xue Y, Li G, Zou L, Zhang X, Ying M, Wang S, Guo L, Gao Y, Li G, et al: Beneficial effects of evodiamine on P2X(4)-mediated inflammatory injury of human umbilical vein endothelial cells due to high glucose. Int Immunopharmacol. 28:1044–1049. 2015. View Article : Google Scholar : PubMed/NCBI
17	Dijkstra S, Mulders PF and Schalken JA: Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clin Biochem. 47:889–896. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kaboli PJ, Rahmat A, Ismail P and Ling KH: MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 97:104–121. 2015. View Article : Google Scholar : PubMed/NCBI
19	Guo H, Li Q, Li W, Zheng T, Zhao S and Liu Z: MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells. Mol Cell Biochem. 390:155–160. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li Z and Wang Y: MiR-96 targets SOX6 and promotes proliferation, migration and invasion of hepatocellular carcinoma. Biochem Cell Biol. Sep 11–2017.(Epub ahead of print). View Article : Google Scholar
21	Xu L, Zhong J, Guo B, Zhu Q, Liang H, Wen N, Yun W and Zhang L: miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol. 37:12023–12032. 2016. View Article : Google Scholar : PubMed/NCBI
22	Cao LL, Xie JW, Lin Y, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY and Huang CM: miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int J Clin Exp Pathol. 7:5582–5594. 2014.PubMed/NCBI
23	Xia H, Chen S, Chen K, Huang H and Ma H: MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother. 68:951–958. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
25	Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM, Sun Y and Chen XF: Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget. 7:42805–42825. 2016.PubMed/NCBI
26	Eissa S, Matboli M, Essawy NO and Kotb YM: Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis. Tumour Biol. 36:9545–9552. 2015. View Article : Google Scholar : PubMed/NCBI
27	Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z, Zhang L, Kang P, Ji D, Jiang X, et al: GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell proliferation. Int J Mol Sci. 15:6314–6327. 2014. View Article : Google Scholar : PubMed/NCBI
28	Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
29	Croce CM and Reed JC: Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res. 76:5914–5920. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yu N, Fu S, Liu Y, Xu Z, Liu Y, Hao J, Wang B and Zhang A: miR-96 suppresses renal cell carcinoma invasion via downregulation of Ezrin expression. J Exp Clin Cancer Res. 34:1072015. View Article : Google Scholar : PubMed/NCBI
31	He FZ, McLeod HL and Zhang W: Current pharmacogenomic studies on hERG potassium channels. Trends Mol Med. 19:227–238. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sanguinetti MC: HERG1 channel agonists and cardiac arrhythmia. Curr Opin Pharmacol. 15:22–27. 2014. View Article : Google Scholar : PubMed/NCBI
33	Litan A and Langhans SA: Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front Cell Neurosci. 9:862015. View Article : Google Scholar : PubMed/NCBI
34	Warmke JW and Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 91:pp. 3438–3442. 1994; View Article : Google Scholar : PubMed/NCBI
35	Lastraioli E, Lottini T, Bencini L, Bernini M and Arcangeli A: hERG1 potassium channels: Novel biomarkers in human solid cancers. Biomed Res Int. 2015:8964322015. View Article : Google Scholar : PubMed/NCBI
36	Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D'Amico M, Masselli M, Iorio J, Callea M, et al: hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer. 112:1076–1087. 2015. View Article : Google Scholar : PubMed/NCBI
37	Pillozzi S and Arcangeli A: Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol. 674:55–67. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zeng W, Liu Q, Chen Z, Wu X, Zhong Y and Wu J: Silencing of hERG1 gene inhibits proliferation and invasion, and induces apoptosis in human osteosarcoma cells by targeting the NF-κB pathway. J Cancer. 7:746–757. 2016. View Article : Google Scholar : PubMed/NCBI
39	Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, Wang B, Yang L, Xu H, Zhang G and Xu Z: HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget. 5:5832–5844. 2014. View Article : Google Scholar : PubMed/NCBI